A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.

Purpose: The aim of this study was to determine the activity and toxicity of two sequential chemotherapy regimens in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Methods: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75 mg/m cisplatin plus 75 mg/m docetaxel, both administered on day 1 every 21 days, followed by three cycles of 1,200 mg/m gemcitabine on days 1 and 8 every 3 weeks (arm A), or three cycles of 25 mg/m cisplatin plus 25 mg/m docetaxel on days 1, 8 and 15 every 28 days, followed by three cycles of 1,200 mg/m gemcitabine on days 1 and 8 every 3 weeks (arm B). Results: Of the evaluable patients, 61% in arm A ( n = 41) and 36% ( n = 44) in arm B completed treatment as per the protocol. The best tumour response rates were as follows (arm A and arm B): complete response: 2.4 and 2.3%; partial response: 39 and 20.4%; stable disease: 26.8 and 13.6%; and progressive disease: 31.8 and 45.4%. The median progression-free and overall survival were 3.9 and 12.3 months in arm A, respectively, 3.1 and 7.7 months in arm B. Grade 3-4 adverse events were more common in arm A. Grade 3-4 neutropenia was the main toxicity observed (56.1% in arm A and 11.4% in arm B). Conclusions: Our data demonstrate the feasibility of a sequential approach of cisplatin plus docetaxel followed by single-agent gemcitabine. Weekly administration of platinum-docetaxel is associated with an improved safety profile but lower efficacy than the conventional three-weekly schedule (registration ID 2004-001044-72). [ABSTRACT FROM AUTHOR]